Policy | April 01, 2024
Venus Remedies receives Rs. 2.50 crore under PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The facility will manufacture tablets, capsules, and injections for the oncology segment
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The new ECO grade is made using renewable feedstock
Lack of technology transfer stands out as a formidable barrier
Subscribe To Our Newsletter & Stay Updated
